Valence ロゴ
人気
ログイン

ウォッチリストに追加

Prime Medicine Inc.

NasdaqGM: PRME · リアルタイム株価 · USD
3.05
-0.12 (-3.79%)
終値時点： Aug 18, 2026, 3:59 PM

Prime Medicine Inc. (PRME) Stock Price, Analysis & Data

-3.79%
買気配2.24
時価総額618.5M
売上高（TTM）4.07M
純利益（TTM）-187.89M
ベータ2.31
EPS（TTM）-1.05
PER（TTM）n/a
予想PER-3.85
PBR（TTM）15.16
PSR（TTM）151.85
Earnings DateNov 6, 2026
売気配3.71
出来高1,263,136
平均出来高（20日）3,250,543
始値3.14
前日終値3.17
当日レンジ3.02 - 3.20
52週レンジ2.67 - 6.94
アナリストBuy
目標株価7.5 (145.90%)
配当n/a
権利落ち日n/a

PRMEについて

Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting i...

[続きを読む]
業種 Biotechnology
セクター Healthcare
IPO日 Oct 20, 2022
従業員数 146
上場取引所 NasdaqGM
ティッカー PRME
ウェブサイト https://primemedicine.com
企業情報の全文

業績

2025年のPrime Medicineの売上高は4.63Mで、前年の2.98Mから55.28%の増加でした。 利益は-201.14Mで、2.69%の増加でした。

財務諸表

アナリスト予想

10件のアナリスト評価によると、PRME株の平均レーティングは「Buy」です。12か月後の目標株価は7.5で、直近株価から145.9%の上昇余地となります。

株価予想

決算サプライズ

Prime MedicineはAug 6, 2026に四半期決算を発表しました：
  • 売上高は $1.15M で、予想を下回りました $0, うち 3.50% の前年比増加にあたります.
  • EPSは -0.24 で、予想を上回りました 0.02, うち 41.46% の前年比増加にあたります.

    • 次回決算発表

    Prime Medicine Inc.の決算発表予定日は Nov 6, 2026, 寄り付き前の予定です。
    アナリストの売上高予想は ... アップグレード
    news image

    1週間前 · Zacks

    Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

    Prime Medicine, Inc. (PRME) delivered earnings and revenue surprises of 0.00% and -73.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    2週間前 · Barrons.com

    Scribe’s Genetic Editing Aims to Prevent Heart Attacks

    Scribe Therapeutics shares are up 30% since it raised $125 million in its initial public offering Friday. The cash will fund three clinical trials testing whether Scribe’s one-time treatments can ha...

    news image

    2週間前 · Zacks

    Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

    Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1か月前 · Insider Monkey

    Bank of America Securities Maintains Buy Rating for Beam Therapeutics (BEAM)

    Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 affordable biotech stocks to buy right now. On July 8, Alec Stranahan from Bank of America Securities reaffirmed his Buy rating for Beam Therapeut...

    news image

    1か月前 · Insider Monkey

    Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics

    Prime Medicine, Inc. (NASDAQ:PRME) is one of the best strong buy penny stocks to invest in now. Prime Medicine, Inc. (NASDAQ:PRME) announced on July 8 a positive, binding resolution of its previously ...

    2ページ中1ページ